Mycophenolate mofetil reduces rejection rates in hepatitis C positive liver transplant recipients.

被引：0
|
作者：
Baillie, GM [1 ]
Taber, DJ [1 ]
Rogers, J [1 ]
Lin, A [1 ]
Baliga, P [1 ]
Chavin, KD [1 ]
机构：
[1] Med Univ S Carolina, Charleston, SC 29425 USA
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1970
引用
收藏
页码：655A / 655A
页数：1
相关论文
共 50 条
  • [1] Mycophenolate mofetil, microemulsion cyclosporine, and prednisone immunotherapy reduces post-transplant rejection in pediatric liver transplant recipients.
    Renz, JF
    Rosenthal, P
    Frankel, W
    Ferrell, LD
    Roberts, JP
    Ascher, NL
    Emond, JC
    [J]. HEPATOLOGY, 1997, 26 (04) : 428 - 428
  • [2] Mycophenolate mofetil, microemulsion cyclosporine, and prednisone immunotherapy reduces post-transplant rejection in pediatric liver transplant recipients.
    Renz, JF
    Frankel, W
    Ferrell, LD
    Roberts, JP
    Emond, JC
    Ascher, NL
    Rosenthal, P
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (02) : 46A - 46A
  • [3] Mycophenolate Mofetil and Tacrolimus Loading Decreases Antibody-Mediated Rejection Rates in Positive Crossmatch Kidney Transplant Recipients.
    Akkina, S.
    Thielke, J.
    Walczak, D.
    Benedetti, E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 488 - 488
  • [4] Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil
    Fasola, CG
    Netto, GJ
    Jennings, LW
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1563 - 1564
  • [5] Delay of hepatitis C recurrence in liver transplant recipients: Impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1561 - 1562
  • [6] Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients
    Kornberg, A.
    Kuepper, B.
    Wilberg, J.
    Tannapfel, A.
    Thrum, K.
    Baerthel, E.
    Hommann, M.
    Settmacher, U.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (04) : 295 - 301
  • [7] A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C
    Jain, A
    Kashyap, R
    Demetris, AJ
    Eghstesad, B
    Pokharna, R
    Fung, JJ
    [J]. LIVER TRANSPLANTATION, 2002, 8 (01) : 40 - 46
  • [8] Mycophenolate mofetil (MMF) therapy for chronic rejection in renal transplant (RTX) recipients.
    Glicklich, D
    Schurter, G
    Greenstein, S
    Mallis, M
    Clemetson, S
    Tellis, V
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A3181 - A3181
  • [9] Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (HEP CR) in liver transplant recipients.
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Sanchez, EQ
    Molmenti, EM
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Klintmalm, GB
    [J]. HEPATOLOGY, 2001, 34 (04) : 639A - 639A
  • [10] The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients.
    Schmidt, LE
    Rasmussen, A
    Norrelykke, MR
    Poulsen, HE
    Hansen, BA
    [J]. HEPATOLOGY, 2001, 34 (04) : 645A - 645A
12345